INTRODUCTION
============

Type 2 diabetes mellitus (T2DM), a complex endocrine and metabolic disorder, is a major public health problem that is rapidly increasing in prevalence worldwide \[[@B1]\]. Although comprehensive diabetes management is important, glycemic control is essential for effective diabetes management because lowering the level of glycated hemoglobin (HbA1c) to below or around 7% can reduce microvascular complications and, if implemented soon after the diagnosis of diabetes, is associated with long-term reduction in macrovascular disease \[[@B2],[@B3]\]. A wide range of pharmacotherapies for glycemic control is now available; however, management of T2DM remains complex and challenging due to its variable pathogenesis, progressive natural history, and limiting side effects of current therapies, including weight gain, hypoglycemia, fluid retention, and gastrointestinal side effects \[[@B4]\]. Furthermore, our current approach to treating hyperglycemia in long-standing diabetes with either established diabetes-associated complications or multiple cardiovascular disease (CVD) risk factors, does not affect the CVD risk \[[@B5],[@B6]\]. Thus, the quest to develop therapeutic agents with novel mechanisms of action, which are expected to fulfill the unmet needs of current therapies, continues.

Although several novel therapies for T2DM are on the horizon, orally administered sodium-glucose cotransporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents that inhibit glucose absorption from the kidney independent of insulin, are promising. They offer a unique opportunity to address the currently unmet therapeutic needs of T2DM patients and to improve their outcomes \[[@B7]\]. The approval by the U.S. Food and Drug Administration (FDA) of two SGLT2 inhibitors, canagliflozin and dapagliflozin, with several others in late-stage clinical development, represents an important step forward in the treatment of T2DM because these drugs may be effective for adults with a high risk of T2DM \[[@B8],[@B9]\]. To determine which patients will benefit most from these drugs, clinicians will have to understand the link between the kidney and glucose homeostasis. This review will focus on the most clinically relevant information on SGLT2 inhibitors. We will also provide the evidence to support their safety and discuss the side effects resulting from their use so that clinicians can prescribe these drugs with confidence.

RENAL GLUCOSE HANDLING: SGLT1 VERSUS SGLT2
==========================================

The kidneys contribute to glucose homeostasis through several mechanisms, including gluconeogenesis, glucose use, and glucose reabsorption from the glomerular filtrate \[[@B10]\]. During glucose reabsorption, for example, approximately 180 L of plasma is filtered daily through the kidneys, which is equivalent to approximately 180 g of glucose, if the average plasma glucose concentration is 100 mg/dL \[[@B11]\]. Under normal physiological conditions, this filtered glucose is almost completely reabsorbed by renal tubular epithelial cells; thus, there is no glucose in urine \[[@B11],[@B12]\]. The transport of glucose into renal tubular epithelial cells is mediated by active cotransporters, the SGLT, a family of ATP-dependent proteins involved in the transport of glucose against a concentration gradient with simultaneous transport of Na^+^ down a concentration gradient \[[@B12]\]. Although six different SGLT genes have been identified in humans, only SGLT1 and SGLT2 have been well characterized, and their roles in glucose transport in the gut and kidney, respectively, have been defined \[[@B12],[@B13]\]. As shown in [Fig. 1](#F1){ref-type="fig"}, the majority of the filtered glucose is reabsorbed through SGLT2, a low-affinity high-capacity transporter located predominantly in the S1 segment of the renal proximal tubule \[[@B7],[@B12]\]. The remainder is reabsorbed through SGLT1, a high-affinity low-capacity transporter located in the S2 and S3 segments of the renal proximal tubule \[[@B7],[@B12]\]. SGLT1 is also involved in glucose absorption from the gastrointestinal tract \[[@B7],[@B12]\]. [Table 1](#T1){ref-type="table"} presents the anatomical locations and biochemical characteristics of SGLT1 and SGLT2. Once the filtered glucose is reabsorbed from the renal proximal tubule via SGLT2 and SGLT1, it is then transported passively into the interstitium through the action of facilitative glucose transporters (GLUTs), such as GLUT1 and GLUT2, at the basolateral membrane of epithelial cells lining the proximal tubule ([Fig. 1](#F1){ref-type="fig"}) \[[@B7],[@B12]\].

RATIONALE FOR THE INHIBITION OF RENAL GLUCOSE UPTAKE
====================================================

Perceiving the kidney as a potential treatment target and \'ally\' in reducing hyperglycemia represents a fundamental change in the perspective for an organ that has been historically thought to be a \'victim\' (nephropathy) in diabetes \[[@B14]\]. However, an improved understanding of the kidney\'s role in glucose homeostasis has prompted the development of novel drugs that reduce the renal reabsorption of glucose, thereby combating hyperglycemia.

The filtered glucose load is the product of the plasma glucose concentration and the glomerular filtration rate (GFR). Therefore, as the plasma glucose concentration increases, the filtered glucose load also increases in a linear manner \[[@B7],[@B12]\]. When the reabsorption capacity of the proximal tubule is surpassed, as occurs during hyperglycemia, glucosuria starts to appear \[[@B7],[@B12]\]. This maximum reabsorption capacity is called as \'the maximum transport rate (Tm)\' \[[@B7],[@B12]\]. In healthy individuals without diabetes, this Tm for glucose is reached at blood glucose concentrations of approximately 200 mg/dL \[[@B15]\]. However, studies in humans with diabetes and experimental animal models of diabetes have consistently reported an increase in the rate of glucose reabsorption in the proximal tubule (i.e., an increase in Tm for glucose) \[[@B16],[@B17]\]. The mean Tm for glucose has been reported to be higher by 20% or more in diabetic patients compared with healthy individuals \[[@B18]\]. Furthermore, an increase in SGLT2 gene expression has been shown to be one of the molecular mechanisms responsible for this increase in Tm for glucose during hyperglycemia \[[@B16],[@B19]\]. During hyperglycemia, the kidney excretes the excess filtered glucose load to restore normoglycemia. By contrast, the diabetic kidney increases the Tm for glucose, thereby exacerbating hyperglycemia by curtailing glucosuria. This attenuated glucosuria, which results from an increase in Tm for glucose in patients with diabetes, might represent a maladaptation to hyperglycemia and underlie the pathogenesis of hyperglycemia \[[@B20]\]. In light of these pathophysiological findings, the abrogation of hyperglycemia and the reduction of renal glucose absorption through the inhibition of SLGTs is a reasonable approach to treat T2DM. [Fig. 2](#F2){ref-type="fig"} shows the renal glucose handling before and after SGLT2 inhibition \[[@B21]\].

PHARMACOLOGICAL INHIBITORS OF RENAL GLUCOSE UPTAKE
==================================================

Phlorizin: proof of concept
---------------------------

Inhibition of SGLT2 has long been regarded as a potential treatment approach for hyperglycemia during T2DM \[[@B22]\]. Phlorizin, a member of the chalcone class of organic compounds, is the prototype SGLT2 inhibitor \[[@B22]\]. It is a naturally-occurring glucoside found in various plants such as in the root bark of the apple tree. It was first isolated in 1835 by a French chemist and subsequently used to treat fever and infectious diseases, particularly malaria \[[@B22]\]. Following the observation that phlorizin induces glucosuria, it became useful in the study of renal function in humans, as the ability of phlorizin to induce glucosuria is indicative of a \'Sound kidney\' \[[@B22]\].

Studies from the 1950s have shown that phlorizin blocks glucose transport in several tissues, including the kidney and small intestine, by inhibiting SGLT proteins \[[@B23]\]. Treatment of partially pancreatectomized diabetic rats with phlorizin induces glucosuria and lowers the blood glucose level \[[@B24]\]. Interestingly, the insulin resistance in these animals also improved \[[@B24]\]. Taken collectively, these findings support the important proof of concept that diabetic patients can benefit from phlorizin treatment.

Although phlorizin inhibits the increase in the blood glucose level in mice treated with a glucose solution, it was not further developed as a therapeutic for T2DM due to several reasons \[[@B22]\]. The reasons include its low selectivity for SGLT2 versus SGLT1, the presence of an active metabolite, and its low oral bioavailability due to poor intestinal absorption \[[@B22]\]. Inhibition of SGLT1 can also result in adverse gastrointestinal effects such as severe diarrhea, dehydration, and malabsorption \[[@B25]\]. Phloretin, the active metabolite of phlorizin, may also produce adverse effects by inhibiting other GLUTs such as GLUT1 and GLUT2 \[[@B26]\]. Due to these limitations, other compounds with greater oral bioavailability and higher selectivity for SGLT2 have been developed. Fortunately, the benign phenomenon observed in subjects with familial renal glucosuria, the genetic disorder caused by mutations in the SGLT2 gene, indicates that the selective inhibition of SGLT2 may be safe \[[@B27]\]. Currently, there are two SGLT2 inhibitors, dapagliflozin and canagliflozin, that are approved globally. Besides these two inhibitors, other SGLT2 inhibitors are currently under development or undergoing clinical trials. In this review, we will discuss the phase III clinical data of dapagliflozin and canagliflozin, with emphasis on their safety and efficacy.

Dapagliflozin
-------------

Dapagliflozin, developed by Bristol-Myers Squibb (New York, NY, USA) and AstraZeneca (Wilmington, DE, USA), is a potent and highly selective SGLT2 inhibitor \[[@B28]\]. Dapagliflozin is rapidly absorbed after oral administration, with a peak plasma concentration within 2 hours of administration \[[@B28]\]. Dapagliflozin has been approved by the European Medicines Agency (EMA) as an adjunct to diet and exercise, in combination with other antidiabetic agents, such as insulin, and as a monotherapy in metformin-intolerant patients in November 2012 \[[@B29]\]. The FDA has also approved dapagliflozin for use in adult patients with T2DM in January 2014 \[[@B30]\]. The efficacy of dapagliflozin in phase III clinical trials with durations of more than 24 weeks is summarized in [Fig. 3](#F3){ref-type="fig"}.

In clinical studies, treatment with oral dapagliflozin either as monotherapy \[[@B31]\], in combination with other oral antidiabetic agents \[[@B32],[@B33],[@B34]\], or as an insulin-based therapy \[[@B35]\] can significantly improve glycemic control and reduce the fasting plasma glucose (FPG) level ([Fig. 3](#F3){ref-type="fig"}), with longer-term extension studies (≥100 weeks) supporting its extended efficacy \[[@B36]\]. The placebo-corrected reduction in the HbA1c level after treatment with dapagliflozin at a dose of 10 mg/day, in combination with one of the above-mentioned agents, ranges from -0.5% to -0.7% ([Fig. 3](#F3){ref-type="fig"}). Furthermore, dapagliflozin decreases body weight by up to 3 kg over a 24-week treatment period \[[@B31],[@B32],[@B33],[@B35]\]. Although body weight increases when dapagliflozin is co-administered with pioglitazone, the increase is smaller than that of the placebo plus pioglitazone groups (0.69 to 1.35 kg vs. 2.99 kg, respectively) ([Fig. 3](#F3){ref-type="fig"}) \[[@B34]\]. The weight reduction in dapagliflozin-treated patients has been reported to be predominantly attributable to reductions in body fat mass \[[@B37]\].

In a double-blind trial using an active comparator, dapagliflozin at a dose of 10 mg/day is as effective as extended-release metformin (titrated to 2,000 mg once daily) in reducing the HbA1c level (-1.45% with dapagliflozin at 10 mg/day vs. -1.4% with metformin) and superior to metformin in reducing the FPG level (-46.4 mg/dL with dapagliflozin at 10 mg/day vs. -34 mg/dL with metformin) in treatment-naïve patients with T2DM \[[@B38]\].

Dapagliflozin has also been studied in initial combination with metformin (titrated to 2,000 mg once daily) in treatment-naïve patients with T2DM. This combination was more effective than either drug alone in reducing the HbA1c level (-1.5% with dapagliflozin at 10 mg/day and -1.4% with metformin vs. -2.0% with dapagliflozin at 10 mg/day and metformin) and the FPG level (-46 mg/dL with dapagliflozin at 10 mg/day and -35 mg/dL with metformin vs. -60 mg/dL with dapagliflozin at 10mg/day and metformin) \[[@B38]\].

Dapagliflozin was also compared with sulfonylurea (glipizide) in patients whose glycemic control was inadequate on metformin. Despite a similar 52-week glycemic efficacy (-0.52% with dapagliflozin at 10 mg/day vs. -0.52% with glipizide titrated to 20 mg/day), dapagliflozin results in a more reduction in body weight and in a lower level of hypoglycemia than glipizide \[[@B39]\]

Canagliflozin
-------------

Canagliflozin (developed by Johnson & Johnson, New Brunswick, NJ, USA) is another SGLT2 inhibitor which became the first SGLT2 inhibitor to be approved in the US in March 2013 \[[@B40]\]. Recently, it was similarly approved by EMA \[[@B41]\]. The efficacy of canagliflozin in phase III clinical trials with durations of more than 24 weeks is summarized in [Fig. 4](#F4){ref-type="fig"}.

Clinical studies have shown that treatment with oral canagliflozin as a monotherapy \[[@B42]\] or in combination with other oral antidiabetic agents \[[@B43],[@B44],[@B45],[@B46]\] significantly improved glycemic control and reduced FPG levels ([Fig. 4](#F4){ref-type="fig"}). After 26 weeks of canagliflozin treatment, there is a significant placebo-corrected reduction in the HbA1c level in patients inadequately controlled with diet and exercise (-0.91% with canagliflozin at 100 mg/day and -1.17% with canagliflozin at 300 mg/day) ([Fig. 4A](#F4){ref-type="fig"}) \[[@B42]\]. Significant reductions in the FPG level and body weight have also been reported ([Fig. 4B and C](#F4){ref-type="fig"}) \[[@B42]\]. In this study, canagliflozin also significantly reduces postprandial glycemic parameters \[[@B42]\], which may be mediated through a delay in glucose absorption via transient SGLT1 inhibition and an increase in urinary glucose excretion via SGLT2 inhibition \[[@B47]\].

In clinical studies, which investigate the efficacy of canagliflozin as an add-on treatment to metformin, canagliflozin is compared with the placebo or sitagliptin at a dose of 100 mg/day \[[@B48]\]. After 26 weeks of treatment with canagliflozin at a dose of 100 or 300 mg/day, there is a reduction of the HbA1c level compared with the placebo (-0.79% with canagliflozin at 100 mg/day and -0.94% with canagliflozin at 300 mg/day vs. -0.17% with the placebo) \[[@B48]\]. After 52 weeks of treatment, canagliflozin at a dose of 100 mg/day or 300 mg/day demonstrates noninferiority, and canagliflozin at a dose of 300 mg/day shows superiority to sitagliptin in lowering the HbA1c level (-0.73% with canagliflozin at 100 mg/day and -0.88% with canagliflozin at 300 mg/day vs. -0.73% with sitagliptin) \[[@B48]\]. In addition, canagliflozin at these doses reduces body weight compared with the placebo and sitagliptin \[[@B48]\].

As secondary agents that are added-on to metformin, canagliflozin at doses of 100 mg/day or 300 mg/day has also been compared with glimepiride (titrated to 8 mg/day) in patients inadequately controlled with metformin \[[@B44]\]. The reduction in the HbA1c level with canagliflozin at a dose of 100 mg/day is noninferior to that of glimepiride (-0.82% with canagliflozin at 100 mg/day vs. -0.81% with glimepiride) \[[@B44]\]. Furthermore, the reduction in the HbA1c level with canagliflozin at a dose of 300 mg/day is superior to that of glimepiride (-0.93% with canagliflozin at 300 mg/day vs. -0.81% with glimepiride) over a 52-week treatment period in patients on background metformin \[[@B44]\]. Canagliflozin at both doses is superior to glimepiride in reducing body weight (-3.7 kg with canagliflozin at 100 mg/day and -4.0 kg with canagliflozinat 300 mg/day vs. 0.7 kg with glimepiride) \[[@B44]\].

The efficacy of canagliflozin is maintained when it is used as a tertiary agent in patients with T2DM who are inadequately controlled with a dual combination such as metformin and sulfonylurea or metformin and pioglitazone \[[@B43],[@B46]\]. Similar to the superiority of canagliflozin 300 mg/day to sitagliptin (100 mg/day) when added as a secondary agent \[[@B48]\], the change in HbA1c with canagliflozin 300 mg/day was superior to that with sitagliptin when they were added in patients inadequately controlled with metformin plus sulfonylurea (-1.03% with canagliflozin 300 mg/day vs. -0.66% with sitagliptin) \[[@B45]\].

In patients inadequately controlled with insulin, with or without additional oral agents, canagliflozin at a dose of 100 mg/day reduces the HbA1c level (-0.73%) over a 28-day treatment period compared with the placebo (-0.19%) \[[@B49]\]. The FPG level (-38.0 mg/dL vs. 8.65 mg/dL) and body weight (-0.73 kg vs. 0.03 kg) are also reduced in patients treated with canagliflozin \[[@B49]\].

Other investigational SGLT2 inhibitors
--------------------------------------

As shown in [Table 2](#T2){ref-type="table"}, several other SGLT2 inhibitors have completed phase III clinical trials or are currently in phase III clinical trials, including empagliflozin (BI 10773) \[[@B50]\], ipragliflozin (ASP 1941) \[[@B51]\], tofogliflozin (CSG 452) \[[@B52]\], luseogliflozin (TS 071) \[[@B53]\], and ertugliflozin (PF 04971729) \[[@B54]\]. Besides these agents, several other SGLT2 inhibitors are currently in phase I/II clinical trials or undergoing preclinical testing.

Empagliflozin, developed by Boehringer Ingelheim (Ingelheim am Rhein, Germany) and Eli Lilly Pharmaceuticals (Indianapolis, IN, USA), is a potent and selective SGLT2 inhibitor, and a New Drug Application has been submitted to the FDA. It has been studied as a monotherapy, and as an add-on to metformin, two oral agents, and insulin \[[@B50]\].

Ipragliflozin, codeveloped by Astellas (Tokyo, Japan) and Kotobuki Pharmaceuticals (Nagano, Japan), is another selective SGLT2 inhibitor that is used in Japan for the treatment of T2DM. It is beneficial as a monotherapy, and as an add-on to metformin or other antihyperglycemic agents such as sulfonylurea or pioglitazone \[[@B51]\].

SAFETY AND TOLERABILITY OF SGLT2 INHIBITORS
===========================================

Phase III clinical trials of dapagliflozin or canagliflozin have shown both agents to be generally well tolerated \[[@B31],[@B32],[@B33],[@B34],[@B35],[@B38],[@B39],[@B42],[@B43],[@B44],[@B45],[@B46]\]. Hypoglycemia is a potential side effect of all hypoglycemic agents. However, hypoglycemia is not anticipated in patients receiving SGLT2 inhibitors because these agents decrease the plasma glucose concentration without augmenting insulin secretion and without inhibiting the counterregulatory response \[[@B12]\]. Indeed, the incidence of hypoglycemia in patients receiving dapagliflozin or canagliflozin was infrequent, occurring at a frequency that is similar to patients receiving a placebo \[[@B31],[@B32],[@B33],[@B34],[@B42],[@B43],[@B46]\]. However, hypoglycemia is more frequent when dapagliflozin or canagliflozin is used in combination with insulin or insulin secretagogue therapy \[[@B35],[@B39],[@B44]\]. Therefore, physicians should reduce the dose of insulin or insulin secretagogue at the time that these SGLT2 inhibitors are initiated. However, in active comparator trials, hypoglycemia has been shown to be less frequent in patients receiving dapagliflozin or canagliflozin compared with those receiving insulin secretagogue therapy \[[@B39],[@B44]\].

SGLT2 inhibitors pose a risk for urinary tract infection (UTI) because they promote glucosuria \[[@B12]\]. As glucosuria is present in diabetic patients, it should be determined whether an aggravation of glucosuria can promote bacterial growth \[[@B12]\]. Indeed, symptoms suggestive of a genital infection and lower UTI are common adverse events in patients receiving dapagliflozin or canagliflozin, and they are reported more frequently in these patients compared with those receiving a placebo or an active comparator \[[@B55],[@B56],[@B57]\]. A pooled safety analysis (n=4,545) shows that genital infections and UTIs are more common in patients receiving dapagliflozin compared with those receiving a placebo, and between-group difference sare less marked for UTIs (genital infection: 4.1% to 5.7% with dapagliflozin vs. 0.9% with the placebo; UTIs: 3.6% to 5.7% with dapagliflozin vs. 3.7% with the placebo) \[[@B55],[@B56]\]. Similar to dapagliflozin, genital infections and UTIs in patients receiving canagliflozin have also been assessed in a pooled analysis of four 24-week phase III studies (n=2,313) \[[@B57]\]. It has been reported that genital infections are more common in the canagliflozin group than in the placebo group, occurring in 11% of women and 4% of men, compared with 3% and 1% in the placebo group, respectively \[[@B57]\]. These events are generally of mild to moderate intensity, and most patients respond to an initial course of standard treatment and rarely discontinue treatment \[[@B57]\]. In this pooled analysis, canagliflozin has been shown to associate with a moderate increase in the incidence of UTIs, with no increase in serious or upper UTIs \[[@B58]\].

An increase in urine volume (up to 400 mL) has been observed in clinical studies with SGLT2 inhibitors \[[@B59]\]. Owing to their mild diuretic effect, several adverse events relating to the reduction in intravascular volume have been observed in clinical trials of dapagliflozin or canagliflozin. These adverse events include orthostatic hypotension, electrolyte imbalance, and a deterioration of renal function \[[@B59]\]. This modest diuretic action of SGLT2 inhibitors is likely to explain the moderate increase in hematocrit (1% to 2%) and the plasma urea nitrogen to creatinine ratio \[[@B12]\]. However, this small increase in urine volume does not associate with an electrolyte imbalance, an acid-base disorder, or nocturia, and it did not affect patient quality of life \[[@B60],[@B61]\].

With regard to the effects of SGLT2 inhibitors on blood pressure (BP), dapagliflozin reduces systolic BP by up to 5 mm Hg, with no significant increase in the heart rate or the occurrence of orthostatic hypotension \[[@B31],[@B32],[@B33],[@B34],[@B35],[@B37],[@B39]\]. The rates of hypotension, dehydration, and hypovolemia are similar in patients receiving dapagliflozin (1% to 2%) compared with those receiving a placebo or an active comparator (0% to 1%) \[[@B31],[@B35]\]. Dapagliflozin treatment does not associate with an increased risk of acute renal toxicity or deterioration of renal function \[[@B62]\]. However, dapagliflozin is not recommended for T2DM patients with moderate to severe renal impairment, end-stage renal disease, or those on dialysis as the mean reduction in the HbA1c level is not significantly different between dapagliflozin (-0.43%) and placebo (-0.32%) in T2DM subjects with moderate renal impairment (an estimated GFR \[eGFR\] between 30 and 59 mL/min/1.73 m^2^) \[[@B63]\].

Similarly, monotherapy with canagliflozin at a dose of 100 mg/day (-3.6 mm Hg) or 300 mg/day (-5.4 mm Hg) for 26 weeks results in a statistically significant reduction in systolic BP compared with the placebo (0.4 mm Hg) \[[@B42]\]. The diastolic BP is also reduced with canagliflozin (-1.6 and -2.0 mm Hg, respectively) versus the placebo (-0.1 mm Hg), although statistical analysis has not been performed \[[@B63]\]. Owing to its mild diuretic effect, several adverse events relating to a reduction in the intravascular volume are observed in canagliflozin trials. These adverse events include pollakiruia (increased urine frequency) and polyuria (increased urine volume), with a frequency generally in the 2% to 5% range, and similar to its comparator \[[@B42],[@B45],[@B64],[@B65]\]. Occurring less frequently, but of greater concern, are the risks of postural dizziness and orthostatic hypotension. Their prevalence has been reported to occur in a dose-dependent manner, appearing in 2.3% and 3.4% of patients receiving canagliflozin at a dose 100 or 300 mg/day, respectively, versus 1.5% of patients receiving an active comparator \[[@B42],[@B44],[@B45],[@B64],[@B65]\]. Factors associating with volume-related adverse effects are older age (≥75 years), concomitant use of loop diuretics, and a moderate renal impairment eGFR between 30 and 59 mL/min/1.73 m^2^ \[[@B66]\]. The small, transient, and reversible decrease in the eGFR observed with canagliflozin therapy is consistent with its hemodynamic effect \[[@B66]\]. The current prescription guidelines for canagliflozin recommend a maximum daily dose of 100 mg for patients with an eGFR between 46 and 59 mL/min/1.73 m^2^. They do not recommend it for subjects with an eGFR \<45 mL/min/1.73 m^2^ based on findings that show these individuals to have a lower glycemic efficacy than those with normal renal function, and a higher incidence of renal-related adverse effects such as hypovolemia and hyperkalemia \[[@B66]\].

Regarding the effect of SGLT2 inhibitors on cardiovascular risk factors other than body weight and BP, a pooled analysis in the dapagliflozin trials concluded that dapagliflozin had an insignificant effect on lipid levels such as small changes in high-density lipoprotein cholesterol (HDL-C; 2.1% to 9.3%), triglycerides (-0.9% to -10.6%) and low-density lipoprotein cholesterol (LDL-C; -0.5% to 9.5%) \[[@B67]\]. In a pooled analysis of the placebo-controlled canagliflozin trials, the placebo-corrected mean percent change from baseline for LDL-C were 4.5% and 8.0% for the canagliflozin 100 and 300 mg/day groups, respectively \[[@B64]\]. The mechanism responsible for this rise in LDL-C is unknown but could result from hemoconcentration or transfer of cholesterol from triglycerides to apolipoprotein B100. However, canagliflozin treatment is proven to improve other lipid parameters such as increases in HDL-C (0.8% to 6.8% with the 100 mg/day and 0.9% to 8.4% with 300 mg/day) and decreases in triglycerides, which may counterbalance the slight rise in LDL-C \[[@B64]\].

Despite there being no evidence of increased teratogenicity in animal studies, there is an increase in the number of breast and bladder cancers in patients receiving dapagliflozin in clinical trials \[[@B68]\]. Breast cancer has been reported in 10 dapagliflozin-treated patients and three placebo-treated patients \[[@B69]\]. All cases of breast cancer have been detected within the first year of the study \[[@B69]\]. Bladder cancer has also been reported in nine dapagliflozin-treated patients and one placebo-treated patient \[[@B69]\]. Hematuria at baseline has been observed in the majority of patients, suggesting a possible pre-existing cancer \[[@B69]\]. In light of these findings, dapagliflozin is not currently recommended for patients with bladder cancer \[[@B70]\]. Furthermore, the FDA has rejected dapagliflozin in January 2012, in part because of breast and bladder cancer concerns. Although the FDA has recently approved dapagliflozin for use in T2DM patients, it is requiring that companies perform several post-marketing studies to determine whether dapagliflozin associates with malignancies \[[@B71]\].

FUTURE PERSPECTIVE
==================

SGLT2 inhibition represents a particularly appealing approach to treat diabetes, in contrast to many other antidiabetic agents, because SGLT2 inhibition does not directly influence insulin secretion, indicating that it utilizes a novel mechanism of action \[[@B7],[@B12]\]. Indeed, the future role of SGLT2 inhibitors in the management of type 1 diabetes mellitus cannot be ruled out, although SGLT2 inhibitors have not yet been tested for this indication. Furthermore, this class of drugs has a unique property of inducing weight loss, which could also be effective in the treatment of obesity and metabolic syndromes \[[@B72]\]. Although the early weight loss is due to mild osmotic diuresis, the progressive long-term reduction in body weight is attributed to a reduction of fat mass, which is attributed to the loss of energy through glucose excretion in urine \[[@B37]\]. Further research is warranted to prove the effects of SGLT2 inhibitors on obesity and metabolic syndromes. However, even when these putative effects of SGLT2 inhibitors are proven, dietary intervention should be enhanced as weight loss can be attenuated by compensatory hyperphagia \[[@B73]\].

While recent trials of other antidiabetic agents have failed to show a definite protective effect for macrovascular outcomes, there is an obvious benefit for microvascular complications \[[@B2],[@B5],[@B6]\]. As SGLT2 inhibitors significantly improve BP, body weight, and glycemic indicators, there is an expectation that these agents will protect not only against microvascular complications but also against macrovascular diseases associated with T2DM. Although the likelihood of these beneficial effects of SGLT2 inhibitors is strong, definite evidence that reliably defines the effects of these agents on vascular events, along with a clear understanding of their safety profile, will be a prerequisite for their widespread use in clinical practice. Currently, several large-scale clinical trials \"Dapagliflozin Effect on Cardiovascular Events\" (DECLARE-TIMI58, NCT-01730534) and \"Canagliflozin Cardiovascular Assessment Study\" (CANVAS, NCT01032629) using dapagliflozin and canagliflozin, respectively\] are ongoing to evaluate the effects of dapagliflozin and canagliflozin on the risk of CVD. Evidence that will define the overall balance of benefits and risks of this new drug class is anticipated within the next 5 years.

CONCLUSIONS
===========

SGLT2 inhibitors prevent glucose reabsorption from renal tubules, thereby promoting urinary glucose excretion and decreasing plasma glucose levels. Current data in humans indicate that SGLT2 inhibitors represent an effective and novel strategy to control the plasma glucose concentration in patients with T2DM. The clinical trials of the most advanced SGLT2 inhibitors, dapagliflozin and canagliflozin, show therapeutic benefits in attaining glycemic control, lowering the plasma glucose level, and reducing the body weight of patients with T2DM. Furthermore, the hypoglycemic episodes associated with SGLT2 inhibitors are mostly mild in severity and not statistically significant compared with the active comparator. Other SGLT2 inhibitors in earlier stages of clinical development also show promising effects on glycemic control. Apart from these effects, several beneficial effects on BP and body weight have also been observed.

As SGLT2 inhibitors have a unique mechanism of action that is independent of insulin secretion or the degree of insulin resistance, the efficacy of this class of drugs is anticipated not to decline with progressive β-cell failure or in the presence of severe insulin resistance \[[@B12]\]. However, as the efficacy of these agents is dependent on glomerular filtration, these therapeutic benefits are limited to a subset of diabetic patients with normal renal function or mild renal dysfunction \[[@B74]\]. Although SGLT2 inhibitors appear to be well tolerated, increased risks of genital infections, and in some studies, UTIs have been reported \[[@B55],[@B56],[@B57],[@B58]\]. Although long-term safety data are required to determine the significance of these observations, time will tell whether this increase in frequency of genitourinary infections will be tolerated by diabetic patients.

The magnitude of the global diabetes problem and the unmet needs of current antidiabetic agents are the primary drivers behind the effort to identify new treatment modalities. Although currently available data indicate that SGLT2 inhibitors fulfill these unmet needs to some extent, larger studies with longer follow-up periods are warranted to establish the long-term safety and efficacy of SGLT2 inhibitors.
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![Glucose reabsorption in the renal proximal tubule. Under normal physiological conditions, the kidney reabsorbs all of the filtered glucose. This occurs via the actions of sodium-glucose cotransporter 2 (SGLT2) in the early proximal tubule, which reabsorbs most of the filtered glucose load, and SGLT1 in the more distal regions of the tubule, which absorbs the remaining glucose. These cotransporters are located on the luminal epithelium. Glucose transporter 2 (GLUT2) and GLUT1 facilitate glucose transport across the basolateral membrane in the early and the more distal regions of the proximal tubule, respectively.](dmj-38-261-g001){#F1}

![Renal glucose handling before and after sodium-glucose cotransporter 2 (SGLT2) inhibition. SGLT2 inhibition reduces the maximum transport rate (Tm) of glucose. This reduced Tm for glucose through SGLT2 inhibition results in a decrease in glucose reabsorption in the renal proximal tubule and lowers the renal threshold so that glucosuria occurs at a lower plasma glucose concentration.](dmj-38-261-g002){#F2}

![Mean changes in (A) the glycated hemoglobin (HbA1c) level, (B) the fasting plasma glucose (FPG) level, and (C) body weight in clinical trials with dapagliflozin at a dose of 5 or 10 mg/day. Data are adjusted for baseline values. MET, metformin; GLIM, glimepiride; PIO, pioglitazone; INS, insulin; NA, not available. ^a^*P*\<0.05 vs. the placebo.](dmj-38-261-g003){#F3}

![Mean changes in (A) the glycated hemoglobin (HbA1c) level, (B) the fasting plasma glucose (FPG) level, and (C) body weight in clinical trials with canagliflozin at a dose of 100 or 300 mg/day. Data are adjusted for baseline values. MET, metformin; SU, sulfonylurea; PIO, pioglitazone; GLIM, glimepiride; SIT, sitagliptin. ^a^*P*\<0.05 vs. the placebo or active comparator.](dmj-38-261-g004){#F4}
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SGLT, sodium-glucose cotransporter.
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SGLT2 Inhibitors in Clinical Development
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IIIFDA, Food and Drug Administration; NDA, New Drug Application; EMA, European Medicines Agency; MAA, Marketing Authorization Application.
